10% of Cathie Wood’s Portfolio Is Invested in Elon Musk-Led Companies

The article warns investors to brace for volatility in both SpaceX and Tesla despite innovation leadership. SpaceX debuted at $150 (about +11% vs IPO), later peaked near $225.64, then fell to about $104.63, and is now around the $135 IPO level; valuation risk is highlighted with a very high P/S of 63.7, even as Q2 results showed 92% YoY revenue growth to $7.8B and reduced net loss from $1B to $541M. For Tesla, shares trade at 178.6x forward earnings with robotaxi success heavily priced in, implying limited margin for error given competitive pressures, and the author suggests not allocating as much as 10% of a portfolio to the two Musk-led names.

Analysis

The market is still paying for optionality, but the important second-order effect is that both names now trade more like duration assets than industrials: small disappointments can reprice them sharply because the current multiple already capitalizes a best-case path. For TSLA, the risk is not just competition in autonomy; it is that any delay in monetizing software/robotaxi narratives leaves the stock exposed to multiple compression before unit growth can re-accelerate. For SPCX, a high sales multiple means public-market holders are effectively underwriting perfect execution with little liquidity buffer, so secondary-market sentiment can swing harder than fundamentals over the next 1-3 quarters.

Near term, the likely winners are profitable, cash-generative AI/innovation proxies with clear earnings cadence, while the losers are long-duration growth baskets that are forced to defend valuation every quarter. That creates a spillover risk into ARKK-style funds and other Musk/innovation adjacency trades: if TSLA stumbles, the de-risking is likely to hit a broader basket of speculative tech names even if their fundamentals are unrelated. Conversely, a clean upside surprise would mostly extend multiple support rather than meaningfully change intrinsic value.

The contrarian point is that the consensus may be over-focusing on whether these are "great companies" and underweighting the path dependency of returns from here. At these valuations, the stock reaction function matters more than the business model: the thesis is less about what they can do in 5 years and more about whether they can avoid any quarter that breaks the market's underwriting assumptions. That makes the setup attractive only for investors with a clear catalyst horizon and strict sizing discipline.

Key Decisions for Investors

• Reduce or avoid fresh TSLA exposure into the next 1-3 earnings cycles; the risk/reward is poor until the market sees two consecutive quarters of margin or autonomy progress that can justify multiple retention.
• Pair trade: long NVDA / short TSLA for the next 1-2 quarters. NVDA still has visible earnings power and capex-linked demand, while TSLA is priced for a cleaner autonomy monetization path than the evidence currently supports.
• If already long TSLA, finance downside with a call spread overwrite or trim into strength ahead of product/regulatory milestones; use any rally on narrative-driven news as an exit opportunity rather than confirmation.
• Stay underweight SPCX until the next quarterly update or secondary-market print confirms that revenue growth is translating into durable free-cash-flow improvement; otherwise it remains a high-beta sentiment vehicle, not a fundamentals compounder.
• Watch ARKK as the broader expression of the risk: if TSLA weakens on a catalyst miss, expect a 1-3 month de-rating across speculative growth names; consider short ARKK vs long QQQ as a cleaner de-risking pair.